Trial Profile

Phase I first in human trial of zavegepant

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 16 Sep 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Zavegepant (Primary)
Indications Migraine
Focus Adverse reactions; First in man; Pharmacokinetics

Most Recent Events

16 Sep 2020 New trial record
10 Sep 2020 According to a Biohaven Pharmaceutical media release, the U.S. Food and Drug Administration (FDA) has authorized the initiation of clinical trials for oral zavegepant and the company has achieved first in human dosing in this trial.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com